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In recent years, photodynamic therapy (PDT) has shown
much promise for the local and selective destruction of
malignant tumours. Although tumour destruction is believed
to be mediated through the production of highly reactive
intermediate singlet oxygen by photoactivated hematopor-
phyrins (Weishaupt et al., 1986), considerable evidence has
accumulated to suggest that the primary site of photo-
dynamic damage is the small vessels and capillaries of the
tumours (Nelson et al., 1988; Berenbaum et al., 1986). Some
studies have shown vascular effects occurring with PDT such
as the fall of tumour -blood flow (Selman et al., 1984;
Wieman et al., 1988) and the shutdown of tumour vessels
(Henderson et al., 1985). In one report a complete cessation
of tumour blood flow was described in rat tumours after
PDT (Star et al., 1986). In solid tumours the drug uptake is
limited by the tissue perfusion rate, the membrane
permeability and the transport across the vessel wall (Ger-
lowski et al., 1986). Therefore, it seemed plausible that
vasoactive drugs might influence tumour destruction by PDT.
In particular the calcium channel blockers have generated
much interest in cancer research since it has been demon-
strated that verapamil, the prototype calcium channel
blocker, increases the cytostatic effects of adriamycin and
vincristine (Tsuruo et al., 1983) and has a reversible anti-
proliferative effect itself (Schmidt et al., 1988). Although the
precise mechanism of action is not known, some studies
indicate that verapamil inhibits the P-glycoprotein pump
which drug-resistant tumour cells use to pump out anticancer
agents (Ince et al., 1986; Garman et al., 1983).
Recently an enhanced photodynamic destruction of
tumours was described when verapamil was concurrently
administered with the photosensitiser, or similarly when
verapamil was injected after PDT, a delay of the regrowth of
tumours was implicated (Cowled & Forbes, 1989). In con-
trast to these authors, who administered high doses of
hematoporphyrin derivative (HPD, 30-50 mg kg-' body
weight), we injected doses of hematoporphyrin derivative
enriched with dihematoporphyrin-ether (DHE, 1.5 or
9mgkg-' body weight) according to previous experiments
(Sroka et al., 1989a). In our experiments we used two
different tumour models to examine the effects of verapamil
on the photodynamic destruction of tumours.
Our first tumour model, the isogeneic fibrosarcoma SSK-2
was implanted into the flank of female inbred C3H-mice.
This fibrosarcoma grows with a doubling time of approxi-
mately 1.5 days. The tumour size was measured with calibra-
tion masks, gauged to the weight of tumours (Kummermehr
& Trott, 1982). The photodynamic efficiency was quantified
by means of the tumour regrowth delay time, i.e. the time a
tumour needs to regain a defined weight (Begg, 1980). When
the tumours reached a weight of 60 mg, the photosensitiser
and verapamil, both diluted with saline solution, were
injected intraperitoneally at a dose of 9 mg kg-' body weight
according to previous experiments (Stocker, 1986). The
values of the individual regrowth delays were plotted and,
assuming their Gaussian statistical distribution, approxi-
mated in a least square fit procedure by an exponential curve.
Mean values and standard deviations of the regrowth delay
have been calculated for a clearer presentation. In addition,
the extent of tumour necrosis after PDT was examined histo-
logically in a second group of tumour bearing mice in order
to compare the regrowth delay with the tumour necrosis.
Our second in vivo model was a human adenocarcinoma of
the colon, heterotransplanted with the standard technique
(Sroka et al., 1989b) into nude mice. When the tumours
reached a 1 cm diameter, the drugs were administered and
the tumours were irradiated.
Five days after PDT the mice were sacrificed and the
tumours were resected. The percentage of the tumour
necrosis was evaluated histologically by three independent
examiners. Mean values and standard deviations of the
tumour necroses were calculated (SAS users guide: Basics
and statistics, 1985).
In both murine tumour models and animals were anaes-
thetised (Inhalation narcosis with Enfluran: Ethrane, Abbot
GmbH, FRG) during the time of irradiation. The mice were
divided into six groups:
Group Treatment
A No drugs, no light, typical growth/spontaneous
necrosis.
B Only photosensitiser administered (DHE).
C Only verapamil administered.
D Only light withoutdrugs.
E Photosensitiser and lightadministered (PDT).
F Photosensitiser + verapamil and light
administered.
In each group, ten animals were treated per experiment.
All experiments were repeated twice so that a total of 30
mice were treated in each group.
Photosan 3 (Seehof Laboratory, FRG), a hematoporphyrin
derivative enriched with dihematoporphyrinether (DHE), was
administered intraperitoneally to the animals at a concentra-
tion of 1.5 mg kg-' (human adenocarcinoma and fibrosar-
coma SSK-2) and 9 mg kg-' (fibrosarcoma SSK-2) body
weight.
Verapamil (Isoptin, Knoll AG, FRG), formulated for
clinical use, was injected concurrently with the photosen-
sitiser at a dose of 2 mg kg-' body weight. Twenty-four
hours after application of of the drugs, the tumours were
irradiated with laser light.
Tumours were treated with laser light tuned to the
wavelength of 630 nm. The radiation was delivered from an
Argon-ion laser-pumped dye laser (model 171 and 375 B,
Spectraphysics Inc., USA; Dye: Kiton red). A tube, covering
the tumour, was fed by a flexible quartz fibre (core diameter:
600gm) and guaranteed nearly homogenous irradiation due
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to multiple inner reflection (Sroka et al., 1989b). The total
energy density was 150 J cm-2 at a power density of
400 mW cm-2. The tube was cooled by a flow of N2 gas in
order to avoid hyperthermic effects at this high power den-
sity. With gas cooling, a maximum temperature of 38°C was
recorded. The temperature was measured subcutaneously
between skin and tumour.
In the fibrosarcoma SSK-2 tumour model the photosen-
sitiser and verapamil were concurrently administered and
tumours were irradiated 24 h later. Both, regrowth delay time
and extent of tissue necrosis of the treated tumours were
examined. The results are shown in Table I and II. These
data show that verapamil did not enhance photodynamic
destruction of tumours. This drug did not markedly affect
the regrowth delay time measured in the fibrosarcoma. The
comparison of tumours treated with PDT plus verapamil
(group F) and PDT alone (group E) showed no effective
inhibition of tumour regrowth. Verapamil alone (group C)
and DHE without irradiation (group B) did not affect the
regrowth delay time.
With respect to the percentage of necrosis measured (Table
II) the tumours demonstrated a similar behaviour in each
group. A concentration of 9 mg kg-' body weight Photosan
3 showed a subtotal destruction of the tumour by PDT
alone. Therefore, the photosensitiser dosage was reduced to
1.5 mg kg-' body weight. At this concentration tumour con-
trol was less effective: There was a significant reduction of
tumour necrosis to 18%. Verapamil plus PDT did not in-
crease the amount of tumour tissue necrosis in both cases.
Verapamil alone (group C) did not affect the tumours macro-
or microscopically.
Our second in vivo model involves tumours of human
adenocarcinoma of the colon which were transplanted into
nude mice. In this model we examined the effects of
verapamil and PDT on tumour destruction alone (Table III).
Under the conditions tested, verapamil did not enhance the
photodynamic destruction of the human colon carcinoma.
Verapamil plus PDT had no effect on the degree of tumour
tissue necrosis when compared to PDT alone. The extent of
tumour necrosis was not influenced by verapamil alone
(group C), DHE alone (group B) or light without drugs
(group D) compared to controls (group A).
The process in which tumour damage is caused by
photodynamic therapy is complex dependent on many
different factors. Experimental studies have shown that the
most important parameters are the applied energy density,
the concentration of the administered photosensitiser in the
tissue and the time interval between irradiation and admini-
stration of the photosensitiser (Barr et al., 1989; Potter et al.,
1987). The photosensitiser uptake and thus the concentration
in tissue are thought to be affected by the tissue perfusion
rate. Therefore, the influence of vasoactive drugs such as
verapamil on PDT was examined in recent studies. Cowled
and Forbes described an increased photodynamic destruction
of tumours with verapamil by using a transplantable tumour
model in mice. In contrast to doses of 30-50 mg kg-' HPD
as used by Cowled and Forbes, low photosensitiser doses
were applied according to previous experiments which proved
to be sufficient to cause a subtotal tumour destruction (Goss-
ner et al., 1991). Higher drug doses did not enhance the
amount of tumour destruction, only the danger of adverse
phototoxic side-effects could possibly increase. Even if these
dosage schedules cannot easily be transferred to clinical
application, it seems to be clear that the lowest possible
photosensitiser concentration should be applied to avoid
phototoxic side-effects of the skin (Wooton et al., 1988).
In view of the results found in our two different tumour
models, we conclude that verapamil does not increase
photodynamic damage concurrently administered with low
doses of DHE in our in vivo models. It could be demon-
strated that for a low photosensitiser concentration neither a
regrowth delay nor an increased extent of tumour tissue
necrosis is achieved. However, in other studies intracellular
concentrations of cytotoxic agents such as adriamycin and
vincristine were increased, suggesting that verapamil im-
proved uptake and inhibited transport of drugs through the
cell membrane (Tsuruo et -al., 1983). Thus the supposed
pharmacological mechanism is the existence of a drug
elimination pathway in the plasma membrane of cancer cells.
A possible explanation could be the concept that verapamil
blocks the P-glycoprotein pump which tumour cells use to
transport anticancer drugs out of the cell (Ince et al., 1986).
But a certain intracellular concentration of the applied drug
has to be reached to activate the P-glycoprotein mechanism.
It is known that the photosensitiser concentration ratio
between tumour and normal tissue is only 2.5:1 (Barr et al.,
1989). In accordance with the P-glycoprotein mechanism
hypothesis, this photosensitiser concentration could be too
low to trigger this drug elimination pathway and might be
the reason why we did not find an enhanced destruction of
Table I Fibrosarcoma SSK-2: Effect of verapamil concurrently administered with DHE on
tumour growth time and regrowth delay time
Animals Growth time (d) Regrowth delay (d)
(n) Mean s.d. Mean s.d.
A Control 30 6.0 1.5 0 0
B DHE alone 30 6.6 0.9 0 0
C Verapamil alone 30 6.5 1.5 0 0
D Light alone (without drugs) 30 5.6 1.1 0 0
E DHE + light (PDT) 30 16.5 3.6 10.5 3.6
F PDT + verapamil 30 17.4 3.8 11.4 3.8
Differences between A through D and E, F are significant (P <0.05).
Table n Fibrosarcoma SSK-2: Influence of verapamil concurrently admini-
stered with DHE on the extent of tumour necrosis
Animals Tumour necrosis (%)
(n) mean s.d.
A Control 30 4.2 4.0
B DHE alone 30 5.0 3.4
C Verapamil alone 30 2.8 1.0
D Light alone (without drugs) 30 4.8 3.2
E DHE + light (PDT) 30 95.3 1.1
30a 18.0 1.6
F PDT + verapamil 30 92.1 6.3
30a 19.8 5.4
Differences between A through D and E, F are significant (P <0.05).
aWith a photosensitiser concentration of 1.5 mg kg-' body weight.86 L. GOSSNER et al.
Table III Human adenocarcinoma of the colon: Effect of verapamil con-
currently administered with DHE on photodynamic tumour destruction
Animals Tumour necrosis (%)
(n) mean s.d.
A Control 30 36.1 10.5
B DHE alone 30 38.7 8.5
C Verapamil alone 30 47.7 4.4
D Light alone (without drugs) 30 42.4 10.0
E DHE + light (PDT) 30 67.5 6.6
F PDT + verapamil 30 70.1 10.0
Differences between A through D and E, F are significant (P <0.05).
malignant tissue by verapamil.
Cowled and Forbes used a different tumour model with
different drug concentrations. Therefore, the question re-
mains to be solved whether the lower photosensitiser concen-
tration or the type of tumour tested is the reason why we did
not find an enhanced tumour destruction in combination
with verapamil. From our results it seems to be clear that
there is no generality in the phenomenon described by
Cowled and Forbes.
In spite of our negative experiments, the possible enhance-
ment of photodynamic destruction of tumours by vasoactive
drugs deserve further investigations. In a recent study,
norverapamil, a mayor metabolite of verapamil with no
systemic side effects, has proved to be as effective as
verapamil (Merry et al., 1989) offering new possibilities in
testing vasoactive drugs and photodynamic therapy.
For low dose administration of DHE, our current experi-
mental strategies comprise different potential modifiers such
as the application of glucose (Thomas & Girotti, 1989) or
improved targeting with liposomes (Jori et al., 1986) or
monoclonal antibodies (Mew et al., 1983).
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